Nemaura Medical Inc

Receive alerts
Market Cap:
$158.07 m
52 weeks high
52 weeks low

Filter by article type

Viewing results 1-20 of 20


Nemaura Medical has a big winner in its painless SugarBEAT glucose monitor

The medtech company is eyeing explosive growth with SugarBEAT, already launching in the UK, followed by the rest of Europe ...

2 weeks, 2 days ago

Nemaura launches shipments of its SugarBEAT glucose monitor to the UK

The SugarBEAT works for patients with diabetes or prediabetes by testing their blood glucose levels using a sensor on the skin, rather than using a needle...

2 weeks, 2 days ago

Nemaura receives $8 million credit facility from major shareholders

The first $3.5 million of the loan will be available to the company immediately, which it plans to use to fund a European Commercial launch...

3 weeks, 1 day ago

Nemaura taps senior healthcare executive to support global launch of SugarBEAT

Chris Avery has launched numerous glucose monitoring devices, stents and insulin pumps into the UK and European markets ...

on 07/18/2019

Nemaura Medical submits De Novo application for SugarBEAT glucose monitor to FDA

For certain low-risk novel devices, the FDA's De Novo pathway offers a swifter route to market and this may speed up SugraBEAT's arrival in the US...

on 07/10/2019

Ascendiant Capital Markets initiates coverage of Nemaura Medical with Buy rating, $3.25 price target

In addition, Acorn Management analyst Peter Wright says research shows the company's SugarBEAT scores over other glucose monitors on ‘multiple counts’ including affordability and cost ...

on 06/21/2019

Nemaura Medical’s painless sugarBEAT glucose monitor wins CE mark

The England-based medtech company will first launch sugarBEAT in the UK, followed by the rest of Europe starting with Germany next quarter ...

on 05/29/2019

Nemaura Medical gives third-party apps access to its SugarBEAT glucose-monitoring data

Users will be able to access SugarBEAT-generated glucose data through their preferred mobile apps...

on 05/02/2019

Nemaura Medical rounds out successful human factors usability study for sugarBEAT glucose monitor

This brings the England-based medical technology company a step closer to submitting its medical device application to the FDA for sugarBEAT...

on 04/23/2019

Nemaura Medical adds new predictive alert function to its sugarBEAT glucose monitor

CEO Faz Chowdhury says adding the alerts and alarms based on predictive algorithms as part of the current CE review process avoids the need for a subsequent CE application...

on 04/16/2019

Nemaura on track for FDA's De Novo submission for sugarBEAT glucose monitor in 2Q

SugarBEAT which has been honed and perfected over seven years is expected to receive CE approval in the UK soon ...

on 03/28/2019

Nemaura rises after supply deal for its SugarBEAT glucose monitor in Mideast

It’s a strategic move to crack open the wealthy markets of Saudi Arabia, Oman, Kuwait and Bahrain...

on 03/12/2019

Nemaura Medical's stock flies ahead of De Novo FDA submission for sugarBEAT glucose monitor

The UK-based medtech company is tapping Dr Fred Schaebsdau to lead strategy and business development ahead of the UK launch and US FDA application...

on 02/11/2019

Nemaura says improved continuous glucose monitor halves time needed for reliable reading

According to Nemaura, a major competitor’s product requires a two-hour ‘warm-up period’ ...

on 01/17/2019

Nemaura Medical announces closing of $2 million offering

The company plans to use part of the funds toward an FDA-approved clinical trial...

on 12/21/2018

Nemaura publishes positive data for De Novo FDA submission, prices $2.5M offering ahead of sugarBEAT launches

SugarBEAT has been honed and perfected over seven years and is expected to receive CE approval in the UK soon...

on 12/18/2018

Nemaura completes clinical studies for De Novo submission to FDA for sugarBEAT glucose monitor

The company plans to apply to the FDA in the first quarter of 2019, which could speed up sugarBEAT’s arrival on American shores...

on 12/04/2018

Nemaura Medical signs pact with Al-Danah Medical to launch painless sugarBEAT glucose monitor in Qatar

It’s a strategic move to crack open the wealthy Qatar market, one of the largest potential markets for continuous glucose monitoring devices ...

on 11/20/2018

Nemaura develops predictive algorithms, alarm functionality for its sugarBEAT glucose monitor

The innovation will make sugarBEAT more appealing and useful to insulin users...

on 11/07/2018

Nemaura is a red hot medtech stock with a winner in its painless sugarBEAT glucose monitor

The medtech company is eying explosive growth with sugarBEAT, on the cusp of launching in the UK, followed by the rest of Europe in 2018...

on 11/05/2018